title: Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.
abstract: Peptide based vaccines offer practical advantages, but unmodified peptides usually require an adjuvant or delivery vehicle to promote immunogenicity. When peptides containing ovalbumin (OVA) derived CD4 and CD8 T cell epitopes were conjugated to 0.05 microm nano-beads, they gave strong immune responses and inhibition of growth of tumour cells expressing the CD8 T cell epitope with MHC class I. These responses were inducible with both high (50 microg) and low (5 microg) peptide doses after a single immunisation. The helper CD4 T cell epitope was unnecessary for induction of CD8 T cell or tumour challenge responses. However, the CD4 T cell epitope contained a B cell epitope and triggered strong antibody responses. This simple approach offers a convenient experimental tool and a potentially useful clinical method for peptide immunisation.
authors.affiliation: Vaccine Development and Infectious Diseases Unit, Austin Research Institute, Austin Hospital, Studley Road, Heidelberg 3084, Vic., Australia.
authors.forename: Theodora
authors.initials: T
authors.lastname: Fifis
authors.forename: Patricia
authors.initials: P
authors.lastname: Mottram
authors.forename: Violeta
authors.initials: V
authors.lastname: Bogdanoska
authors.forename: Jennifer
authors.initials: J
authors.lastname: Hanley
authors.forename: Magdalena
authors.initials: M
authors.lastname: Plebanski
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm; D000939:Epitopes / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D015395:Histocompatibility Antigens Class I / Q000737:chemistry / Q000494:pharmacology*; D000949:Histocompatibility Antigens Class II / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D036103:Nanotechnology; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic